U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795659) titled 'Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)' on Jan. 21.
Brief Summary: This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food & Drug Administration (FDA) for treatment resistant depression. Combined with PE, in...